Home > Riviste > Minerva Medica > Fascicoli precedenti > Articoli online first > Minerva Medica 2016 Oct 04

ULTIMO FASCICOLOMINERVA MEDICA

Rivista di Medicina Interna


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

Minerva Medica 2016 Oct 04

lingua: Inglese

Intraoperative radiotherapy in gastric and esophageal cancer: meta-analysis of long-term outcomes and complications

Peng GAO 1, Chengche TSAI 1, Yuchong YANG 1, Yingying XU 2, Changwang ZHANG 1, Cong ZHANG 1, Longyi WANG 1, Hongpeng LIU 1, Zhenning WANG 1

1 Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, Heping District, Shenyang
City, China; 2 Department of Breast Cancer, First Hospital of China Medical University, Heping District, Shenyang City, China


PDF  ESTRATTI


BACKGROUND: The treatment effects of intraoperative radiotherapy (IORT) for gastric and esophageal cancer remain uncertain. We therefore performed meta-analyses to investigate whether IORT was associated with more favorable oncologic outcomes when compared to non-IORT for patients who have gastric or esophageal cancer.
METHODS: PubMed, Embase, and the references of relevant studies were systematically searched up to March 2016. Outcomes were analyzed with fixed-effect or random-effect models, and the meta-analysis was completed with odds ratio (OR), hazards ratio (HR), and 95% confidence intervals (CI) as effect values.
RESULTS: Eleven studies were included, nine for gastric cancer and two for esophageal cancer. The studies included 1581 patients, 570 in the IORT group and 1011 in the control group. There was no significant difference in overall survival (OS) between the IORT group and control group (HR=0.91, 95% CI=0.73-1.13; P=0.38). Two subgroups based on cancer type also had the similar results (gastric group: HR=0.98, 95% CI=0.78–1.24, P=0.87; esophagus group: HR=0.63, 95% CI=0.37–1.05, P=0.08). Besides, IORT showed favorable effects for patients with cancer in stage II and stage III and had the advantage of locoregional control. Regarding the complications, the occurrence rate had no significant difference between the IORT group and control group (OR=1.15; 95% CI=0.77–1.72; P=0.50).
CONCLUSIONS: According to our meta-analysis, IORT did not extend the OS in gastric cancer and esophageal cancer patients, but had a favorable effect for specific stage patients to show locoregional control, and did not increase the risk of complications.

inizio pagina